Common drug review new combination product : indication : type 2 diabetes mellitusErtugliflozin/Metformin fixed-dose combination (Segluromet) Merck Canada Inc
Diabetes mellitus is a metabolic disease that is characterized by persistent elevations in blood glucose (hyperglycemia). This persistent elevated blood glucose causes damage to blood vessels on a microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (peripheral artery disease, cardiovascular disease) level. Diabetes is one of the most common chronic diseases in Canada. Diabetes Canada estimated there were 3.4 million people (9.3% of the population) with diabetes in 2015 and, by 2025, this number will increase to five million people (12.1%). The objective was to perform a systematic review of the beneficial and harmful effects of ertugliflozin 5 mg and 15 mg tablets in combination with metformin, or metformin and sitagliptin, to improve glycemic control in adult patients with type 2 diabetes mellitus when these therapies, along with diet and exercise, do not provide adequate glycemic control. This review was conducted in tandem with the evaluation of ertugliflozin 5 mg and 15 mg tablets (Steglatro), which includes additional study data and an appraisal of the manufacturer-submitted indirect treatment comparison that are not included in this report..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
February 2019 |
|---|---|
| Erschienen: |
Ottawa (ON): CADTH ; February 2019 |
| Ausgabe: |
Final (with redactions). |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Bridged Bicyclo Compounds, Heterocyclic |
|---|
| Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed November 21, 2019) |
|---|
| Umfang: |
1 online resource (1 PDF file (77 pages)). |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1773190539 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1773190539 | ||
| 003 | DE-627 | ||
| 005 | 20230428011956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1773190539 | ||
| 035 | |a (DE-599)KEP068708629 | ||
| 035 | |a (NCBI)9917506193406676 | ||
| 035 | |a (EBP)068708629 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Common drug review new combination product |b indication : type 2 diabetes mellitusErtugliflozin/Metformin fixed-dose combination (Segluromet) Merck Canada Inc |
| 250 | |a Final (with redactions). | ||
| 264 | 1 | |a Ottawa (ON) |b CADTH |c February 2019 | |
| 300 | |a 1 online resource (1 PDF file (77 pages)). | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH common drug review | |
| 500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed November 21, 2019) | ||
| 520 | |a Diabetes mellitus is a metabolic disease that is characterized by persistent elevations in blood glucose (hyperglycemia). This persistent elevated blood glucose causes damage to blood vessels on a microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (peripheral artery disease, cardiovascular disease) level. Diabetes is one of the most common chronic diseases in Canada. Diabetes Canada estimated there were 3.4 million people (9.3% of the population) with diabetes in 2015 and, by 2025, this number will increase to five million people (12.1%). The objective was to perform a systematic review of the beneficial and harmful effects of ertugliflozin 5 mg and 15 mg tablets in combination with metformin, or metformin and sitagliptin, to improve glycemic control in adult patients with type 2 diabetes mellitus when these therapies, along with diet and exercise, do not provide adequate glycemic control. This review was conducted in tandem with the evaluation of ertugliflozin 5 mg and 15 mg tablets (Steglatro), which includes additional study data and an appraisal of the manufacturer-submitted indirect treatment comparison that are not included in this report. | ||
| 650 | 2 | |a Diabetes Mellitus, Type 2 |x drug therapy |0 https://id.nlm.nih.gov/mesh/D003924Q000188 | |
| 650 | 2 | |a Metformin |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D008687Q000627 | |
| 650 | 2 | |a Metformin |x adverse effects |0 https://id.nlm.nih.gov/mesh/D008687Q000009 | |
| 650 | 2 | |a Bridged Bicyclo Compounds, Heterocyclic |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D019086Q000627 | |
| 650 | 2 | |a Bridged Bicyclo Compounds, Heterocyclic |x adverse effects |0 https://id.nlm.nih.gov/mesh/D019086Q000009 | |
| 650 | 2 | |a Sodium-Glucose Transporter 2 Inhibitors |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D000077203Q000627 | |
| 650 | 2 | |a Sodium-Glucose Transporter 2 Inhibitors |x adverse effects |0 https://id.nlm.nih.gov/mesh/D000077203Q000009 | |
| 650 | 2 | |a Drug Combinations |0 https://id.nlm.nih.gov/mesh/D004338 | |
| 650 | 2 | |a Comparative Effectiveness Research |0 https://id.nlm.nih.gov/mesh/D057186 | |
| 651 | 2 | |a Canada |0 https://id.nlm.nih.gov/mesh/D002170 | |
| 655 | 2 | |a Systematic Review |0 https://id.nlm.nih.gov/mesh/D000078182 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK542579/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994087511 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 399401378X |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 399979013X |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995678025 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987680334 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987764538 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK542579/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK542579/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK542579/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK542579/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK542579/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||